The US Food and Drug Administration (FDA) has approved the first oral N-methyl D-aspartate (NMDA) receptor antagonist for the treatment of major depressive disorder (MDD) in adults, its manufacturer has announced.
Auvelity (Axsome Therapeutics) is a proprietary extended-release oral tablet containing dextromethorphan (45 mg) and bupropion (105 mg).
It is the "first and only rapid-acting oral medicine approved for the treatment of MDD with labeling of statistically significant antidepressant efficacy compared to placebo starting at one week," the company said in a news release.
"The approval of Auvelity represents a milestone in depression treatment based on its novel oral NMDA antagonist mechanism, its rapid antidepressant efficacy demonstrated in controlled trials, and a relatively favorable safety profile," Maurizio Fava, MD, psychiatrist-in-chief, Massachusetts General Hospital, Boston, added in the release.
"Milestone" in Depression Treatment?
Fava noted that nearly two thirds of patients treated with currently available antidepressants fail to respond adequately, and those who do may not achieve clinically meaningful responses for up to 6-8 weeks.
"Given the debilitating nature of depression, the efficacy of Auvelity observed at 1 week and sustained thereafter may have a significant impact on the current treatment paradigm for this condition," he said.
The company noted the drug was studied in a comprehensive clinical program that included more than 1100 patients with MDD.
The efficacy of the drug was demonstrated in the GEMINI placebo-controlled study — with confirmatory evidence provided by the ASCEND study, which compared it with bupropion sustained-release tablets.
Axsome said it expects to launch the new oral medication in the fourth quarter of this year. It is not approved for use in children.
Lead image: Axsome Therapeutics
© 2022 WebMD, LLC
Send news tips to email@example.com.
Cite this: FDA Approves 'Rapid-Acting' Oral Drug for Major Depression - Medscape - Aug 22, 2022.